ACRO Applauds Nomination of Dr. Scott Gottlieb as FDA Commissioner

WASHINGTON--()--Doug Peddicord, PhD, Executive Director of the Association of Clinical Research Organizations, today issued the following statement regarding President Trump’s nomination of Dr. Scott Gottlieb to serve as the next Commissioner of the Food and Drug Administration.

“ACRO applauds the thoughtful nomination of Dr. Gottlieb as FDA Commissioner. We believe Dr. Gottlieb will strike the appropriate balance of encouraging innovation while ensuring the safety and efficacy of new drugs. We look forward to working with him and his team, especially on implementation of the 21st Century Cures Act where ACRO’s members have particular interest and expertise in areas such as real-world evidence, patient-focused drug development and innovative clinical trial designs.”

About ACRO

The Association of Clinical Research Organizations (ACRO) represents companies that provide a variety of specialized services that support the development of new pharmaceuticals, biologics, and medical devices. Through its member companies, ACRO helps improve the quality, efficiency and safety of biomedical research. ACRO member companies employ more than 130,000 professionals worldwide and conduct research in more than 100 countries. For more information, please visit www.acrohealth.org. Twitter @acrohealth. YouTube @ACROHealthChannel. Facebook. LinkedIn.

Contacts

Association of Clinical Research Organizations
John Lewis, 202-464-9340
jlewis@acrohealth.org

Release Summary

Association of Clinical Research Organizations (ACRO) Applauds Nomination of Dr. Scott Gottlieb to be FDA Commissioner

Contacts

Association of Clinical Research Organizations
John Lewis, 202-464-9340
jlewis@acrohealth.org